Updated time: 2021-11-03 17:39:07
12A-1040109
TW I651092、US 10835493 B2、CN 107847442 B、JP 6874995
Ischemic heart diseases continue to be the leading causes of deaths in many countries. Although developing novel therapeutics and identifying new potential drug targets, the therapeutic applications of these potential treatments are still limited. It has demonstrated that platelets aggregate on the surfaces of the circulating monocytes happens during the development of ischemic heart disease. Thus, a good strategy would be to develop a drug delivery vehicle that has platelet membrane proteins on its surface and utilize the circulating monocytes as a ‘shuttle bus’ to allow the encapsulated drugs to reach the targeted site specifically.
Although tremendous efforts have been made in these areas, typically, <3% of an intravenous-injected drug will be retained in the myocardium. The major limitation is the lack of any long-term enhanced permeability and retention (EPR) effect following MI, unlike tumors which sustain the EPR effect for a long duration. Existing nanotechnologies solely rely on EPR effect to retain at the in the myocardium. Therefore, there is an urgent and unmet need to develop novel materials that could facilitate drug targeted therapy to the infarcted heart without EPR effect manner.
It is hypothesized the anti-inflammatory therapeutic encapsulated in PLP would enter the infarct heart area through the interactions of the delivery vehicle with the circulating monocytes. Therefore, this technology can apply to any ischemic disease such as heart ischemia and stroke. Besides, it also found that massive monocytes infiltrate in tumors because of cancer cell overgrowth. It can also apply to cancer targeting treatment.
Patrick CH Hsieh, Bill Cheng
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Platelet-like proteo-microparticles and method of using such in drug delivery